A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Parkinson's Disease
Interventions
DRUG

Rotigotine

"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."

Trial Locations (12)

Unknown

Augsburg

Bochum

Bonn

Bremerhaven

Dortmund

Dresden

Hanau

Ingolstadt

Kiel

Schwerin

Stralsund

Ulm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY